医药行业数字化转型加速，医药供应链领域正经历结构性变革，竞争转向科技赋能与模式创新。作为A 股创业板医药供应链龙头，国内首家上市的医药产业 互联网 企业 药易购 （股票代码：300937）立足行 业趋势，在升级核心医药供应链业务的同时，持续加码创新业务，通过科技赋能构筑长期竞争壁垒，其 前瞻性布局不仅契合行业发展方向，更具备极强的资本市场长期布局价值。 我国医药行业正处于高质量发展转型期，2026年AI医疗拐点确立，行业展望指出"AI赋能+基本面反 转"将成为核心增长引擎，这为医药供应链企业的创新升级提供了广阔空间。"十四五"期间药品供应链 市场规模持续扩容，2024年销售额达2.95万亿元，其 中药 品零售市场6500亿元。商务部等9部门印发相 关意见，推动药品零售行业数字化、规范化发展，为药易购创新布局提供了重要政策支撑，也进一步打 开了药易购等公司新业务的资本想象空间。 随着医药科技进步、政策完善以及AI医疗拐点确立，行业集中度将持续提升，具备科技优势、新赛道 布局前瞻的企业将获得更大发展空间，也将成为资本市场的核心关注标的。药易购的创新布局精准契合 行业方向，新赛道多点开花，长期价值增长确定性强，有望 ...

证券代码：300937 证券简称：药易购 公告编号：2026-001 四川合纵药易购医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 二、与会计师事务所沟通情况 本次业绩预告是四川合纵药易购医药股份有限公司（以下简称"公司"）财 务中心初步测算的结果，未经负责公司年报审计的会计师事务所审计，公司已就 业绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在本次业 绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、公司医药供应链等业务整体运营稳健，保持稳定的市场表现，但整体市 场环境和行业政策变化，零售端结构调整、基层终端需求转移、渠道与消费行为 转变等因素叠加对公司盈利产生影响。 2、公司积极布局的新业务目前仍处于前期培育阶段，相关研发投入、市场 开拓及渠道建设等费用持续发生，暂未形成规模化收入与盈利贡献。为优化资源 2025 年度业绩预告 4、计提资产减值准备， ...

1月23日，A股市场医药商业股集体上涨，其中，人民同泰、益丰药房涨停，鹭燕医药涨超7%，大参林涨超6%， 九州通涨超5%，重药控股、药易购、海王生物、合富中国、漱玉平民涨超4%。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 消息面上，商务部等9部门发文提出：完善药事服务，提升药学服务能力，促进处方流转提升购药体验，优化定点 零售药店门诊统筹服务，推动药品零售企业参加药品集中采购等措施。鼓励药品零售企业依法开展横向并购与重 组。鼓励创新药、参比制剂等药品进零售药店销售渠道。鼓励医药电商平台开放数据接口，加强线上、线下药品 零售价与省级医药采购平台挂网价的联动监测，加强定点药店医保药品量价比较指数和药品比价小程序的推广应 用。 | 代码 | 名称 | 0 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | | --- | --- | --- | --- | --- | --- | --- | | 600829 | 人民同泰 | 事 | 10.04 | 72.43亿 | 15.54 | 12.49 | | 603939 | 益丰药房 | 1 | 10.02 | 301亿 | 14.23 | 2 ...

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

药店零售股23日盘中集体走高，截至发稿，人民同泰、益丰药房、九州通、重药控股涨停，药易购、大 参林涨超9%。 消息面上，1月22日，商务部等九部门发布了《关于促进药品零售行业高质量发展的意见》。其中提 出，鼓励药品零售企业依法开展横向并购与重组。鼓励各地优化营商环境，对于被整合的连锁或单体药 店，优化《药品经营许可证》申请核发流程。鼓励药品批发企业依法通过兼并重组整合供应链与零售终 端，推动批零一体化发展，实现仓储物流资源共用、质量管理体系协同及全流程信息追溯，提升供应链 效率，有效降低运营成本。倡导医药生产企业与全国或区域大型医药流通企业深度合作，以市场为导向 规范药品购、销价格体系，促进药品零售行业跨省、跨地区公平竞争，引导零售药品价格保持合理水 平。 （文章来源：证券时报网） 国金证券指出，政策持续推动行业规范发展的背景下，药店合规龙头优先受益。且率先进行门店调整的 龙头公司，2025年三季度收入端边际回暖。内生表现向好，且部分龙头公司现金流状况优秀，有望在出 清期趁势提升市占率；另外，部分公司开始尝试积极拓展非药，优化产品结构，作为纯增量业务来看， 非药后续若迎来超预期的表现，有望成为潜在的重要利润贡 ...

Group 1 - The company, Yiyigou (300937.SZ), stated that it currently has no relationship with WiNGPT and has not engaged in any collaboration with Ant Group's Aifu in the medical AI sector [1]

Core Viewpoint - The company emphasizes the importance of artificial intelligence and advanced technologies in enhancing its core business and has established a subsidiary to strengthen its digital ecosystem [2] Group 1: Company Initiatives - The company has set up a subsidiary named Shutan Artificial Intelligence to enhance its digital capabilities [2] - The company has completed the localization deployment of DeepSeek, which is part of its efforts to promote internal digital transformation and external ecosystem empowerment [2] - These initiatives aim to improve the efficiency of the industry chain and empower upstream and downstream partners, thereby enhancing the company's long-term competitiveness [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

1月14日，药易购涨5.12%，截至发稿，报42.48元/股，成交2.63亿元，换手率10.47%，总市值40.64亿 元。药易购股价已经连续3天上涨，区间累计涨幅14.22%。 截至发稿，孔宪政累计任职时间5年50天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 93.39%， 任职期间最差基金回报-16.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，四川合纵药易购医药股份有限公司位于四川省成都市金牛区友联一街18号13层，成立日期 2007年4月28日，上市日期2021年1月27日，公司主营业务涉及院外市场的医药类产品批发及零售。主营 业务收入构成为：药品(化药)99.27%，其他(补充)0.73%。 责任编辑：小浪快报 从药易购十大流通股东角度 数据显示，诺安基金旗下1只基金位居药易购十大流通股东。诺安多策略混合A（320016）三季度新进 十大流通股东，持有股数56.4万股，占流通股的比例为0.92%。根据测算，今日浮盈赚取约116 ...

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]